Thrombosis market- significant revenue opportunity; Morgan Stanley report

Thrombosis is the formation of a blood clot within a blood vessel resulting in the restriction of blood flow through the circulatory system, and remains the world's largest single cause of mortality, despite the fact that medication has been available for over 50 years to treat and prevent the condition. A report by analysts at Morgan Stanley forecasts the global market size for this indication to increase from $5.1 billion in 2002 to $16.2 billion in 2010, with 65% of this revenue growth expected to come from the US market.

Unmet medical need

The treatment of thrombosis and associated disorders, including stroke, myocardial infarction and pulmonary embolism, is currently largely through the use of aspirin, warfarin and heparin, which are all off-patent drugs. The report suggests that the deficiencies in the existing therapies in terms of their efficacy and safety, represents a significant revenue generating opportunity for pharmaceutical companies.